Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon’s FY2019 Sales Up 5.1% on Equa/EquMet Addition
May 14, 2020
- Roche Diagnostics Rolls Out Coronavirus Antibody Detection Reagents in Japan
May 14, 2020
- Ono to Test Pancreatitis Med Foipan for COVID-19: President
May 13, 2020
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
- Xofluza Sees Sharp Sales Decline, but Inavir Logs Growth: 2019-2020 Flu Drug Market
May 13, 2020
- Keytruda Keeps Top Spot in April Drug Ranking: Encise
May 12, 2020
- Shionogi Suffers Lower Earnings as Xofluza Sales Dive 98.4% in FY2019
May 12, 2020
- Santen Snaps Up Exclusive Rights for US Biotech’s Eye Cell Therapy in Japan, Asia, Europe
May 12, 2020
- Daiichi Sankyo Chairman Nakayama to Step Aside as Adviser
May 12, 2020
- Mylan EPD Curbing Nesp Biosimilar Supplies amid Big Demand
May 11, 2020
- Novartis Offers Free Access Program for Zolgensma Diagnostic
May 11, 2020
- Jitsubo Licenses Peptide Manufacturing Technology to Bachem
May 11, 2020
- Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
- Chugai Begins Joint Research with Singapore Agency on Novel Antibody Drug for COVID-19
May 11, 2020
- 4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
May 11, 2020
- Astellas to Carry on Teleworking through End of May
May 11, 2020
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
- Daiichi Sankyo Seeks Gastric Cancer Use for Enhertu
May 8, 2020
- Sales Rep Promotions Decrease 34%, Seminars Down 84%: Intage
May 8, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…